Showing results (1-10 of 22) with videos related to
Sort By:
Pageof 3
The Oncologist|February 21, 2002
The cardiotoxic potential of the 5-HT(3) receptor antagonist antiemetics: is there cause for concern?Deborah L KeefeJournal of Clinical Pharmacology|December 17, 2011
Efficacy, safety, and tolerability of aliskiren monotherapy administered with a light meal in elderly hypertensive patients: a randomized, double-blind, placebo-controlled, dose-response evaluation studyGiuseppe Villa, Stephanie Le Breton, Ghionul Ibram, et al.Journal of Clinical Hypertension (Greenwich, Conn.)|December 7, 2011
Comparison of aliskiren/hydrochlorothiazide combination therapy and amlodipine monotherapy in patients with stage 2 systolic hypertension and type 2 diabetes mellitusRaymond R Townsend, Alan D Forker, Vaishali Bhosekar, et al.Hypertension Research : Official Journal of the Japanese Society of Hypertension|March 6, 2009
Long-term safety, tolerability, and antihypertensive efficacy of aliskiren, an oral direct renin inhibitor, in Japanese patients with hypertensionToshio Kushiro, Hiroshige Itakura, Yoshihisa Abo, et al.Hypertension (Dallas, Tex. : 1979)|March 14, 2007
Direct Renin inhibition with aliskiren in obese patients with arterial hypertensionJens Jordan, Stefan Engeli, Sam W Boye, et al.Hypertension Research : Official Journal of the Japanese Society of Hypertension|March 24, 2007
Aliskiren, a novel oral renin inhibitor, provides dose-dependent efficacy and placebo-like tolerability in Japanese patients with hypertensionToshio Kushiro, Hiroshige Itakura, Yoshihisa Abo, et al.Journal of Hypertension|May 16, 2009
Aliskiren-based therapy lowers blood pressure more effectively than hydrochlorothiazide-based therapy in obese patients with hypertension: sub-analysis of a 52-week, randomized, double-blind trialRoland E Schmieder, Thomas Philipp, Javier Guerediaga, et al.Clinical Drug Investigation|November 1, 2011
Long-term safety and tolerability of the oral direct renin inhibitor aliskiren with optional add-on hydrochlorothiazide in patients with hypertension: a randomized, open-label, parallel-group, multicentre, dose-escalation study with an extension phaseDomenic Sica, Alan H Gradman, Ole Lederballe, et al.Journal of the American College of Cardiology|March 21, 2007
Aliskiren, an oral renin inhibitor, provides dose-dependent efficacy and sustained 24-hour blood pressure control in patients with hypertensionByung-Hee Oh, Jerry Mitchell, James R Herron, et al.Pageof 3